Crofelemer in Intestinal Failure

Crofelemer in Intestinal Failure

Short Bowel Syndrome with Intestinal Failure (SBS-IF)

World icon

An estimated
10,000-20,000
individuals in the US have
IF due to SBS1

Intestinal failure (IF) is defined as the reduction of intestinal function such that fluids and nutrients given by the enteral or parenteral (PN) route are needed to maintain health

Intestine Icon

Home parenteral nutrition
can cost patients
$100k-$150k
a year in the US1

SBS-IF is a complex condition characterized by severe malabsorption of fluids and nutrients due to surgical resection of bowel segments, congenital anomalies, or disease-associated loss of absorption requiring parenteral nutritional support for survival

30% of people icon

The mortality rate of SBS
patients on home parenteral
nutrition is about
30% after 5 years1

SBS patients suffer from malnutrition, dehydration, imbalances of fluids and salts, and excessive intestinal fluid output

Crofelemer’s ability to regulate ion channels in the gut normalizes the salt and water balance in the small bowel, which may lead to better absorption of fluids and nutrients in those living with SBS-IF

Research & Development

  • The initial focus of Napo Therapeutics, an Italian corporation established by Jaguar Health in Italy, is on pursuing the conditional marketing authorization pathway from the European Medicines Agency for crofelemer for SBS-IF and congenital diarrheal disorders (CDD)
  • Planning to complete a global trial (in collaboration with Napo Pharmaceuticals) in SBS-IF patients suitable for the conditional approval pathway in the EU

Research & Development

  • The initial focus of Napo Therapeutics, an Italian corporation established by Jaguar Health in Italy, is on pursuing the conditional marketing authorization pathway from the European Medicines Agency for crofelemer for SBS-IF and congenital diarrheal disorders (CDD)
  • Planning to complete a global trial (in collaboration with Napo Pharmaceuticals) in SBS-IF patients suitable for the conditional approval pathway in the EU
Injector Icon

Orphan-Drug Designation

  • Crofelemer has received orphan-drug designation in the US and European Union for SBS
  • Crofelemer has received orphan-drug designation in the European Union for Microvillus Inclusion Disease (MVID), a rare congenital diarrheal disorder (CDD) condition

Orphan-Drug Designation

  • Crofelemer has received orphan-drug designation in the US and European Union for SBS
  • Crofelemer has received orphan-drug designation in the European Union for Microvillus Inclusion Disease (MVID), a rare congenital diarrheal disorder (CDD) condition
Injector Icon

Congenital Diarrheal Disorders (CDD)

Rare Congenital Chronic Intestinal Channel Disease

Parentage Icon

Occurring in Early Infancy

CDD patients experience severe, lifelong diarrhea—the incidence is highest in regions where consanguineous marriage is more common

Lifelong Need Icon

Unmet Needs

Patients endure a lifelong need for nutritional intake, either parenterally or via a feeding tube

Research & Development

  • In vitro confirmation of activity required by FDA
  • Jaguar is currently supporting an investigator-initiated proof-of-concept study of crofelemer in patients with SBS or CDD with intestinal failure, with a planned endpoint of reduction of requirement of weekly volume of parenteral nutrition

Reference: 1. Schalamon J, Mayr JM, Höllwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol. 2003;17(6):931-942. doi:10.1016/s1521-6918(03)00079-9

Research and Development Icon
Research and Development Icon

Research & Development

  • In vitro confirmation of activity required by FDA
  • Jaguar is currently supporting an investigator-initiated proof-of-concept study of crofelemer in patients with SBS or CDD with intestinal failure, with a planned endpoint of reduction of requirement of weekly volume of parenteral nutrition

Reference: 1. Schalamon J, Mayr JM, Höllwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol. 2003;17(6):931-942. doi:10.1016/s1521-6918(03)00079-9